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Abstract
Background
Central pain mechanisms may be prominent in subsets of patients with rheumatoid arthritis
(RA), psoriatic arthritis (PsA) and other spondyloarthritis (SpA). The painDETECT question-
naire (PDQ) identifies neuropathic pain features, which may act as a proxy for centrally
mediated pain.
The objectives were to quantify and characterize pain phenotypes (non-neuropathic vs.
neuropathic features) among Danish arthritis patients using the PDQ, and to assess the
association with on-going inflammation.
Methods
The PDQ was included onto the DANBIO touch screens at 22 departments of Rheumatol-
ogy in Denmark for six months. Clinical data and patient reported outcomes were obtained
from DANBIO. A PDQ-score >18 indicated neuropathic pain features, 13–18 unclear pain
mechanism and <13 non-neuropathic pain.
Results
Pain data (visual analogue scale, VAS) was available for 15,978 patients. 7,054 patients com-
pleted the PDQ (RA: 3,826, PsA: 1,180, SpA: 1,093). 52% of all patients and 63% of PDQ-
completers had VAS pain score 30 mm. The distribution of the PDQ classification-groups
(<13/ 13-18/ >18) were; RA: 56%/24%/20%. PsA: 45%/ 27%/ 28%. SpA: 55% / 24%/ 21%.
More patients with PsA had PDQ score >18 compared to RA and SpA (p<0.001). For PDQ >
18 significantly higher scores were found for all patient reported outcomes and disease activity
scores. No clinical difference in CRP or swollen joint count was found. Logistic regression
showed increased odds for having VAS pain39 mm (the median) for a PDQ-score >18 com-
pared to <13 (OR = 10.4; 95%CI 8.6–12.5).
PLOS ONE | https://doi.org/10.1371/journal.pone.0180014 July 7, 2017 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Rifbjerg-Madsen S, Christensen AW,
Christensen R, Hetland ML, Bliddal H, Kristensen
LE, et al. (2017) Pain and pain mechanisms in
patients with inflammatory arthritis: A Danish
nationwide cross-sectional DANBIO registry
survey. PLoS ONE 12(7): e0180014. https://doi.
org/10.1371/journal.pone.0180014
Editor: Peter M ten Klooster, University of Twente,
NETHERLANDS
Received: May 25, 2016
Accepted: June 7, 2017
Published: July 7, 2017
Copyright: © 2017 Rifbjerg-Madsen et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data are available
from the Danish national rheumatolgic quality
registry, DANBIO, for researchers who meet the
Danish legal criteria for access to confidential data.
Contact: databasen@danbio-online.dk or www.
rkkp.dk.
Funding: SRM recieved grants from Selsbjerg
Holding, The Danish Rheumatism Association,
Minister Erna Hamiltons Legat for Videnskab og
Kunst, Axel Muusfeldts Fond, Dagmar Marshalls
Conclusions
More than 50% of the Danish arthritis patients reported clinically significant pain. More than
20% of the PDQ-completers had indication of neuropathic pain features, which was related
to a high pain-level. PDQ-score was associated with DAS28-CRP and VAS pain but not with
indicators of peripheral inflammation (CRP and SJC). Thus, pain classification by PDQ may
assist in mechanism-based pain treatment.
Introduction
Pain in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other spondyloarthritis (SpA)
is traditionally considered to be of peripheral nociceptive origin, i.e. pain elicited by activation
of afferent sensory nerve fibers (C-fibers) in the inflamed synovium [1]. Increased responsive-
ness of peripheral and central nociceptive neurons, i.e. pain hypersensitivity, is a normal
response (neuroplasticity) in the presence of inflammation. However, pain hypersensitivity
may persist after the inflammation has ceased and thus become a manifestation of maladaptive
pathological changes in the central nervous system leading to chronic pain [2].
Chronic pain has been most thoroughly investigated in RA where pain is reported to persist
despite regression of inflammatory signs [3] and emerging data suggest a role of augmented
central pain processing, including central sensitization and dysfunction of descending pain
modulating systems in subsets of patients [4]. Fibromyalgia (FM), by many considered the
prototypical central pain syndrome, is more common in RA than in the general population
with reported prevalence estimates of up to 20% [5]. A co-diagnosis of FM in RA is associated
with poorer outcome of anti-inflammatory treatment when evaluated by pain ratings and
composite disease activity scores [5;6]. However, it is likely that not only individuals with RA
and concomitant FM have abnormal central pain processing. There is probably a continuum
of pain hypersensitivity among patients with RA that may influence patient-reported outcomes
and disease activity evaluations [6]. Subserving pain mechanisms in PsA and SpA are less well
examined and studies have mainly focused on co-occurrence of FM. The reported prevalence
of FM ranges from 4% to 15% for SpA and 17% to 53% for PsA depending on screening tool
and gender [7–11].
Treatment of inflammatory arthritis is based on disease activity measures that are fully or
partially composed of subjective indicators related to pain perception. Pain hypersensitivity
may lead to continuous high reports of for example tender joints, pain and poor global health
and thus an overestimation of inflammatory activity. Identification of possible underlying pain
mechanisms may, therefore, be of great importance and assist clinical decision making. The
painDETECT questionnaire (PDQ) is a patient administered screening questionnaire origi-
nally developed to identify neuropathic pain [12]. Based on pain phenotypic similarities, the
PDQ has been used to assess neuropathic pain features as a proxy of central pain mechanisms
in patients with osteoarthritis and fibromyalgia [13–18]. Recently, the PDQ has also been
introduced in studies of smaller samples of patients with RA [19;20] and SpA [21] reporting
neuropathic pain features in subsets of patients.
The purpose of this study was to report the prevalence of pain phenotypes (non-neuro-
pathic vs. neuropathic pain features) as assessed by the PDQ in the Danish arthritis population
(RA, PsA and other SpA) and to investigate the association between pain phenotype and
inflammation. Furthermore, the study aimed to describe differences in patient characteristics
across PDQ-classification groups.
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Patients and methods
Study design and setting
The study was designed as a descriptive, cross sectional survey including patients registered in
DANBIO, the Danish nationwide rheumatologic registry (Protocol; http://parkerinst.dk/
research). The DANBIO-registry is a clinical quality assurance registry which was initiated in
year 2000. It is based on Danish rheumatologists registering and continuously reporting data
on their patients diagnosed with inflammatory arthritis when seen in daily care. It covers
>90% of adults treated with biologics due to rheumatic disease and data on patients treated
with disease-modifying antirheumatic drugs, DMARDs, are also collected [22–24].
Following local approval of the project at the departments, an electronic version of the
PDQ was implemented nationally on the DANBIO touch screens in the waiting room at 22 of
24 departments of Rheumatology in Denmark for a period of six months (1.Dec 2013-1.June
2014). All patients registered as having any form of RA, PsA, other SpA, unspecific arthritis
(UA) or ‘no diagnosis’ were eligible and invited to participate in the survey. Patients were
asked to accept participation, decline or indicate ‘no pain 4 weeks prior to the survey’ on the
touch screens. Patients choosing the two latter categories were excluded from filling in the
PDQ, while clinical data from DANBIO were obtainable from all patients visiting the touch
screens in the study period.
The primary focus was on the diagnostic groups: RA, PsA and other SpA. All patients were
included in the overall pain analysis, while only patients with a complete PDQ response were
included in the PDQ subanalyses. The first complete questionnaire and corresponding clinical
data from the same date were extracted for analyses (CRP +/- 14 days).
Patient consent was obtained on the touch screen prior to the redirection to the PDQ.
According to Danish legislation, surveys do not require approval by Ethics Committees and
registrations and publications of data from clinical registries do not require patient consent or
approval by Ethics Committees. Approval was obtained from the Danish Data Protection
Agency.
Variables and outcome measures
The PDQ is a symptom-based assessment tool originally developed to assist identification of
neuropathic pain in patient with low back pain [12]. It is composed of items reflecting pain
intensity (three numeric rating scales), pain course pattern, a pain drawing intended for indi-
cation of pain radiation, and seven questions describing somatosensory signs and symptoms
considered characteristic for neuropathic pain rated on a six-category Likert scale (from never
to very strongly). A total score ranging from -1 to 38 is calculated based on the patient’s
answers. Pain intensity ratings are not included in the total score; selection of pain course pat-
tern contributes to the total score with a value ranging from -1 to 1; the absence/presence of
radiating pain with a value of 0 or 2; and the presence and severity of evaluated somatosensory
signs and symptoms with a value ranging from 0 to 35. For diagnostic purposes, a validated
algorithm is used to classify pain into three groups: a score >18 indicate that presence of a pre-
dominant neuropathic pain component is likely, a score<13 indicated that it is not, while a
score of 13–18 is considered indecisive; i.e., a neuropathic pain component cannot be ruled
out. [12]. The questionnaire is reported to have a sensitivity of 84% and likewise a specificity of
84% (electronic version) when applied for pain classification in a mixed chronic pain popula-
tion [12]. Satisfactory psychometric properties of the PDQ have been demonstrated within
osteoarthritis by Morton et al.[25], and within inflammatory arthritis by our group (in
review).
Pain and pain mechanisms in inflammatory arthritis
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Information on demographics and treatment were registered according to the DANBIO
registry standard. Before consulting their rheumatologist patients regularly complete com-
monly used standardized patients reported outcomes (Table 1) on the DANBIO touch screens
in the doctor’s waiting room. All patients complete visual analogue scale (VAS) pain, VAS
fatigue, and VAS global health, which are 0–100 mm scales, where 100 mm indicates the worst
imaginable pain/fatigue/ general health. Depending on their diagnosis patients furthermore
complete a disability index. For patients with peripheral joint disease the health assessment
questionnaire (HAQ)[26], an index reflecting level of function in daily living is used. For
patients with axial joint disease the Bath ankylosing spondylitis function index (BASFI) is used
[27]. Finally the Bath ankylosing spondylitis disease activity index (BASDAI) is used to register
overall disease activity in this patient group [28;29]. The two latter questionnaires include
questions on pain, disability and function related to the axial and large joints. The rheumatolo-
gists register corresponding clinical outcomes hence different disease activity scores are avail-
able in the DANBIO registry:
DAS28-crp (disease activity score 28 joints–CRP) [30] used for peripheral joint disease:
0:56 
p
ðTJC28Þ þ 0:28 
p
ðSJC28Þ þ 0:36  lnðCRPþ 1Þ þ 0:014  GH þ 0:96
ASDAS (ankylosing spondylitis disease activity score) [31] used for axial joint disease:
0:12  Back Painþ 0:06  Duration of Morning Stiffnessþ 0:11  Patient Global
þ0:07  Peripheral Pain=Swelling þ 0:5 Ln ðCRPþ 1Þ
BASMI-365 (Bath ankylosing spondylitis metrology index undertaken within the last year)
[32]: a standardized clinical examination reporting degree of joint stiffness.
Statistical analysis
SAS software (version 9.3; SAS Institute Inc., Cary; North Carolina, USA) was used for the
statistical analyses. The PROC UNIVARIATE statement was used for visual inspection of the
distribution of variables. Potential group differences were tested using the non-parametric
Table 1. Overview of patient reported outcome measures and disease activity scores available in the DANBIO registry.
Variable Collected in disease area Unit and range* Aims to assess Nature of variable#
VAS pain RA/PsA/SpA 0–100 mm Pain intensity Self-reported
VAS fatigue RA/PsA/SpA 0–100 mm Fatigue severity Self-reported
VAS global health RA/PsA/SpA 0–100 mm Impact on global health Self-reported
HAQ RA/PsA 0–3 Disability Self-reported
BASMI PsA/SpA 0–100** Spinal mobility Clinical examination
BASFI PsA/SpA 0–100** Disability Self-reported
BASDAI PsA/SpA 0–100** Overall disease activity Self-reported
DAS28-CRP RA /PsA 0–10 Overall disease activity Combination
ASDAS PsA/SpA 0–6.3*** Overall disease activity Combination
*No unit specified indicates an arbitrary unit
** As used in the DANBIO registry
***Maximum scores on all self-reported items (0–10) and CRP 100.
# The nature can be either: Self-reported, clinical examination or a combination of variables that are self-reported, objective and the result of a clinical
examination
https://doi.org/10.1371/journal.pone.0180014.t001
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Kruskal-Wallis test for continuous variables and Chi-square test for categorical variables. Cor-
recting for multiple testing (65 repeated tests) two-sided p-values < 0.001 (0.05/65) were
regarded as statistically significant when comparing potential PDQ classification-group differ-
ences. Due to the ‘real life’ character of DANBIO complete data for all variables were not avail-
able. Only available data were used for calculations.
To address the possible presence of sensitization in more ways also the swollen to tender
joint count ratio (STR) was calculated according to previously published procedures [33] and
compared across PDQ classification-groups using the PROC FREQ procedure.
To quantify a potential increased risk for rating higher than or equal to the median VAS-
pain associated with the PDQ classification-groups (<13 = low, 13–18 = intermediate,
>18 = high) logistic regression analysis was performed. For pragmatic reasons the median
VAS for PDQ-completers was chosen as cut off (39 mm). Prior to conducting the logistic
regression, an analysis of possible interaction between the PDQ classification-group and diag-
nosis was performed, which proved insignificant (y = ‘diagnosis’ ‘PDQ classification-group’
‘diagnosisPDQ classification-group’ (interaction); p-value for interaction = 0.76, p-value for
PDQ ‘classification-group’ <0.001, p-value for ‘diagnosis’ < 0.001). Hence, the ‘PDQ classifi-
cation-group’ and ‘diagnosis’ were applied as main effects in the unadjusted Model 1. Separate
models were run for each pain classification and disease comparison. Based on clinical signifi-
cance and plausibility the following a priori selected confounders were included in the
adjusted Model 1: sex, age, disease duration, CRP, and status of treatment with biologics (yes/
no). Accepted level of covariance between independent variables was Spearman’s Rho < 0.3.
Backward deletion of variables with a p-value > 0.1 was performed to make a more parsimoni-
ous adjusted model (Model 2). Results from the logistic regression analyses are reported as
odds ratios with confidence intervals (95%CI).
Results
Flow of respondents and sampling process
Fig 1 illustrates the patient flow. A total of 15,978 patients belonging to either of the following
diagnostic groups; RA, PsA, other SpA, unspecific arthritis (UA) or ‘no diagnose’ were invited
to participate in the study (visited the touch screens in the period). Standard clinical data from
DANBIO were available on these patients. Of those 7,918 accepted to fill in the PDQ and 7,054
completed all items in the questionnaire and were assigned a score. A total of 6,133 patients
declined participation, while 1,927 registered themselves as being pain-free, thus principally
excluding themselves from filling in the PDQ. The median (IQR) level of VAS pain reported
as standard in the DANBIO-registry for all invited participants was 31 (14–55) mm, 39 (21–
63) mm for PDQ-completers, 30 (14–53) mm for declining participants and 8 (2–20) mm for
participants categorizing themselves as pain-free in the introductory touch screen form. Of all
patients visiting the touch screen 52% (7,483/14,339) had a VAS pain 30 mm while the num-
bers were 63% (3,991/6,380) among PDQ-completers, 51% (2,799/5,471) for declining partici-
pants and 15% (262/1,712) for participants reporting to be pain-free.
PDQ classification across arthritis diagnoses
The main results of this study, the distribution of the PDQ classification-groups (<13/ 13-18/
>18), are illustrated in Fig 2. More than 20% across all diagnoses had a PDQ score> 18 indic-
ative of primarily neuropathic pain features. A total of 28% of PsA patients had a PDQ scores
> 18 which was significantly higher than for patients with RA and SpA (p<0.001). Also statis-
tically significantly fewer PsA patients had a PDQ score < 13 (p<0.001) indicating primarily
non-neuropathic pain.
Pain and pain mechanisms in inflammatory arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0180014 July 7, 2017 5 / 16
Participant demographics and clinical characteristics
Patient characteristics stratified by PDQ-score are shown in Table 2. Treatment with DMARDs
included: methotrexate (MTX), sulfasalazine, leflunomide, chloroquine and azathioprine. Treat-
ment with Biologics primarily included one of the following agents: infliximab, eternacept, adali-
mumab, golimumab, certolizumab, abatacept, tocilizumab, or rituximab. MTX in either mono
or combination therapy was used in 71% of RA, 58% of PsA and 15% of SpA patients.
A higher number of women was observed in the higher PDQ classification-groups along
with higher absolute values of all patient reported outcomes e.g. patient’s scores for pain,
fatigue, global health and disability (HAQ, BASFI), doctor’s global score and disease activity
scores for the three diseases (DAS28-CRP, BASDAI, ASDAS). There were no differences
across PDQ classification-groups in CRP, serology and current treatment with a biological
Fig 1. Flowchart of possible participants in the painDETECT survey. RA: rheumatoid arthritis; PsA: psoriatic arthritis;
SpA: other Spondyloarthritis; UA unspecified arthritis; Dx: diagnosis.
https://doi.org/10.1371/journal.pone.0180014.g001
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agent. Furthermore, the median swollen joint count (SJC) was 0 for all categories; however the
interquartile range varied slightly (p<0.001).
Some differences across PDQ classification-groups only related to one of the diagnoses:
In patients with RA, higher tender joint count (TJC) and number of patients currently
treated with DMARD and previously treated with Biologics were observed in the higher PDQ
classification-group, while age was higher in the low PDQ classification-group.
In PsA patients higher absolute values in the higher PDQ-classification-groups for TJC and
higher fraction of patients treated with more than one biological drug were seen.
In patients with other SpA a lower proportion of HLA-B27 positive patients was observed
in the higher PDQ classification-groups, though not (borderline) statistical significant.
Finally, a stratified analysis of the number of biologic agents received by the patients (first,
second, third or fourth or more) did not reveal any differences.
BMI only differed across PDQ-classification-groups for RA-patients (p<0.001), where a
higher value was observed in the higher classification-groups, while no difference in smoking
habits was observed for any diagnosis (data not shown).
Swollen to tender joint count ratio
The proportions of STR groups within PDQ classification-group are shown in Table 3. Higher
proportions of a low STR, reflecting the single patient having more tender than swollen joints,
Fig 2. Distribution of painDETECT classification-groups (<13/ 13-18/ >18). * p < 0.001.
https://doi.org/10.1371/journal.pone.0180014.g002
Pain and pain mechanisms in inflammatory arthritis
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Table 2. Patient characteristics stratified by painDETECT classification-group.
n
<13
PDQ score
13–18 >18 P-value
Demographics
Patients, total (n) RA 3826 2136 903 787 <0.001†
PsA 1180 527 321 332 <0.001†
SpA 1093 598 268 227 <0.001†
Female sex n(%)a RA 2766 1455 (68) 674 (75) 637 (81) <0.001†
PsA 666 235 (45) 193 (60) 238 (72) <0.001†
SpA 436 194(32) 123 (46) 119 (52) <0.001†
Age (yrs) RA 3826 61 (52–69) 59 (51–67) 59 (51–66) <0.001†
PsA 1180 53 (43–61) 52 (44–60) 52 (42–60) 0.227
SpA 1093 45 (36–55) 45 (37–55) 43 (36–53) 0.213
Disease durationb RA 3470 8(3–16) 8(3–15) 8(3–15) 0.573
PsA 1000 7 (3–12) 5 (2–10) 5 (2–10) 0.004
SpA 953 7 (3–15) 5 (2–10) 4 (2–10) 0.001
Treatment intensity
DMARDS n(%) RA 3216 1829(86) 749(83) 647(82) 0.035
PsA 792 349(66) 222(69) 221(67) 0.656
SpA 237 122(20) 62(23) 53(23) 0.527
DMARDS>1c RA 777 395(18) 197(22) 185(24) 0.005
PsA 79 27 (5) 25(8) 27(8) 0.150
SpA 18 12 (2) 3 (1) 3 (1) 0.581
Current bio n(%) RA 1341 730(34) 328(36) 283(36) 0.439
PsA 458 212(40) 121(38) 125(38) 0.670
SpA 646 362 (61) 153(57) 131 (58) 0.566
Bio >1d RA 875 422 (50) 240 (59) 213 (59) 0.002
PsA 263 88 (36) 72 (51) 103 (61) <0.001†
SpA 349 162(40) 93 (49) 94 (59) 0.003
DMARDs previous bioe RA 204 80 (4) 60 (7) 64 (8) <0.001†
PsA 59 20 (4) 13(4) 26(8) 0.020
SpA 11 7 (1) 7(3) 4 (2) 0.302
Prednisolone n(%) RA 376 188 (9) 87 (10) 101 (13) 0.005
PsA 28 12 (2) 6 (2) 10 (3) 0.619
SpA 11 8 (1) 2 (1) 1 (0.5) 0.456
PROs
VAS pain RA 3508 26 (14–44) 43 (27–61) 61 (43–77) <0.001†
PsA 1071 27 (15–46) 49.5 (29–69) 69 (52–81) <0.001†
SpA 995 30 (16–53) 53 (36–71) 68.5 (52–82) <0.001†
VAS fatigue RA 3508 34 (17–57) 54 (34–72) 72 (54–85) <0.001†
PsA 1070 35 (17–57) 63.5 (40–80) 78 (62–90) <0.001†
SpA 995 40 (22.5–66) 65 (41.5–81) 77 (60–88) <0.001†
VAS GH RA 3522 29 (15–53) 51 (31–68) 70 (52–84) <0.001†
PsA 1071 30 (15–57) 58 (34–78) 77 (59–89) <0.001†
SpA 994 33.5 (19–56) 63 (39.5–77.5) 75 (59–87) <0.001†
HAQ RA 3506 0.5 (0.125–1) 1 (0.5–1.375) 1.375(1–1.875) <0.001†
PsA 1046 0.375(0.125–0.75) 0.875(0.5–1.375) 1.375(1–1.875) <0.001†
BASDAI PsA 1002 29 (15–46) 53 (36–68) 70 (55–83) <0.001†
SpA 923 31.5 (17–48) 53 (35–66) 68 (53–79) <0.001†
(Continued )
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were seen across PDQ classification-groups with the highest proportions in the high PDQ clas-
sification group. A high STR, reflecting the single patient having more swollen than tender
joints, was seen in limited proportions of patients across the PDQ classification-groups with
the lowest proportion in the high PDQ classification-group. More patients with PsA than with
RA had low STR.
Logistic regression
The results of the logistic regression analysis quantifying the risk of high pain rating are shown
in Table 4. The cut off point for the dependent variable ‘VAS pain for PDQ-completers’ was 39
mm. For each of the models, the high and the intermediate, the high and the low, and the
Table 2. (Continued)
n
<13
PDQ score
13–18 >18 P-value
BASFI PsA 1001 22 (8–38) 42.5 (26–61) 65 (46–81) <0.001†
SpA 921 23 (11–43) 38 (21–58) 58 (41–77) <0.001†
Disease activity scores
VAS doctor RA 3058 7 (3–14) 10 (4–19) 13 (6.5–26) <0.001†
PsA 900 8 (3–15) 10 (5–20) 15 (7–25) <0.001†
SpA 609 6 (2–15) 9 (4–16) 12 (5–25) <0.001†
DAS28-CRP RA 3046 2.4 (1.9–3.3) 3(2.3–3.9) 3.7 (2.8–4.7) <0.001†
PsA 825 2.4 (1.8–3.0) 3.1(2.3–3.9) 3.7 (2.7–4.6) <0.001†
SJC RA 3282 0 (0–1) 0 (0–2) 0 (0–2) <0.001†
PsA 946 0 (0–0) 0 (0–1) 0 (0–1) 0.007
TJC RA 3295 0 (0–2) 1 (0–5) 4 (0–9) <0.001†
PsA 956 0 (0–2) 1 (0–4) 4 (0–9) <0.001†
ASDAS PsA 823 2 (1.4–2.7) 2.6 (2.1–3.55) 3.45 (2.7–3.95) <0.001†
SpA 697 2 (1.4–2.8) 2.9 (2.2–3.3) 3.2 (2.6–3.9) <0.001†
BASMI-365 PsA 299 10 (0–20) 10 (0–30) 20 (10–30) 0.004
SpA 921 10 (0–40) 20 (10–30) 20 (10–40) 0.010
Biochemistry
CRP mg/l RA 3231 4 (2–9) 4 (1–9) 4 (2–10) 0.067
PsA 914 3 (1–6) 3 (1–7) 4 (2–7) 0.446
SpA 775 3 (1–7) 3 (1–7) 3 (1–8) 0.736
RF n(%) RA 3091* 1388 (78) 575 (78) 455 (78) 0.968
antiCCP n(%) RA 1908* 579 (53) 221 (48) 173 (48) 0.122
HLA-B27 n(%) PsA 128* 36 (60) 21 (58) 13 (41) 0.180
SpA 367* 167 (82) 61 (71) 45 (58) 0.002
All values are the median (Q1-Q3) unless otherwise specified. Group differences were tested using Kruskal-Wallis test or Chi-square test.
a: Refers to the fraction of women in each subgroup of PDQ classification. b: Time since diagnosis. c: Receives a combination of DMARDs. d: Have
received more than one biologic agent. e: Currently treated with DMARDs and previously treated with a biologic agent.
† Remain significant after adjusting for multiple testing.
*Number of patients with available information (pos/neg).
PDQ-score: painDETECT Questionnaire score; DMARDs: disease modifying anti-rheumatic drugs; Bio: biological agent; PROs: patient reported outcomes;
VAS: visual analogue scale (mm); GH: global health; DAS28-CRP: disease activity score 28 joints; CRP: C- reactive protein; SJC: swollen joint count; TJC:
tender joint count. HAQ: health assessment questionnaire; ASDAS: ankylosing spondylitis disease activity score; BASDAI: Bath ankylosing spondylitis
disease activity index; BASMI 365: Bath ankylosing spondylitis metrology index attained within the last year; RF: rheumatoid factor; antiCCP: cyclic
citrullinated peptide antibody; HLA-B27: human leucocyte antibody, subtype B27.
https://doi.org/10.1371/journal.pone.0180014.t002
Pain and pain mechanisms in inflammatory arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0180014 July 7, 2017 9 / 16
intermediate and the low PDQ classification-groups were compared. Also the diagnoses were
mutually compared. Of the a priori chosen confounders ‘disease duration’ was insignificant in
the adjusted model 1 (p = 0.89) and was therefore omitted in the adjusted model 2. Results
were robust across all models. The highest OR’s for having at or above the median VAS pain
score were seen in the high PDQ-classification-group compared with the low PDQ classifica-
tion-group. Thus, it was more likely for the patients in the high PDQ classification group to
have a VAS pain score at or above the median than for patients in the intermediate or low
PDQ classification-group.
The patients with PsA and SpA were more likely to have a VAS pain score at or above the
median compared to patients with RA.
Discussion
Pain and pain phenotype prevalence
This registry-based, nationwide cross-sectional study of Danish patients with inflammatory
arthritis showed that despite intensive treatment and generally low disease activity scores, 63
percent reported clinical significant residual pain (VAS pain 30 mm). This number was 52
percent in the overall study population (n = 14339). Clinically acceptable levels of pain in
patients with inflammatory diseases are, however, a matter of debate. Wolfe et al., including
12,090 patients with RA, reported the best cut-point for an acceptable level of pain to be 2.0 on
Table 3. Proportions n (%) of STR groups within PDQ classification-groups.
Diagnosis PDQ <13 (n (%)) PDQ 13–18 (n (%)) PDQ >18 (n (%)) p-value
Low STR < 0,5 RA 601(61.4) 310 (60.0) 336 (67.0) <0.001
PsA 134 (71.3) 132 (75.4) 149 (78.8)
Moderate STR 0.5–1.0 RA 317 (32.4) 181 (35.5) 151 (30.0) 0.101
PsA 48 (25.5) 39 (22.3) 37 (29.6)
High STR > 1.0 RA 61 (6.2) 26 (5.0) 15 (3.0) 0.045*
PsA 6 (3.2) 4 (2.3) 3 (1.6)
Chi square test was used to compare groups. Overall Chi-Square tests: RA, p = 0.03; PsA, p = 0.52.
*Fisher’s exact test
https://doi.org/10.1371/journal.pone.0180014.t003
Table 4. Logistic regression analysis for modeling high pain status (median VAS pain of 39 mm).
Odds ratio (95%CI)
Model 1 Model 1 Model 2
Variables unadjusted adjusted adjusted
PDQgroup H vs. I 2.9 (2.4–3.5) 2.9 (2.3–3.5) 2.9 (2.4–3.5)
PDQgroup H vs. L 9.6 (8.3–11.6) 10.2 (8.4–12.4) 10.4 (8.6–12.5)
PDQgroup I vs. L 3.4 (2.9–3.8) 3.6 (3.0–4.2) 3.6 (3.1–4.2)
PsA vs RA 1.2 (1.0.-1.4) 1.6 (1.3–1.9) 1.5 (1.3–1.8)
SpA vs RA 1.6 (1.4–1.9) 2.3 (1.2–2.3) 2.5 (2.0–3.0)
SpA vs PsA 1.4 (1.1–1.6) 1.5 (1.2–1.9) 1.6 (1.3–2.0)
PDQgroup: painDETECT classification-group. H: high (>18), I: intermediate (13–18), L: low (<13).
Prior to regression analysis an analysis of interaction was performed; PDQgroup p<0.001, Diagnosis p< 0.001, PDQgroup*Diagnosis p = 0.76.
Model 1 adjusted: A priori defined potential confounders: sex, age, disease duration, CRP, and Biological treatment (yes/no).
Model 2 adjusted: Omitting ‘disease duration’ (p = 0.89): sex, age, CRP, and Biological treatment (yes/no).
https://doi.org/10.1371/journal.pone.0180014.t004
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a 10 cm VAS [34], whereas Tubach et al., in their study of 1,532 patients with different rheu-
matologic diagnoses, reported the patient acceptable symptom level to be 42 on a 0–100 scale
for pain [35]. It, therefore, seems reasonably to conclude that clinically meaningful pain was
present in a large proportion of the study population.
Of the subsample evaluated with the PDQ (n = 7054), more than 20% had a PDQ-
score > 18, indicating the presence of primarily neuropathic pain features, while 45–56%
depending on diagnosis had a score < 13 indicating the absence of such pain characteristics.
In comparison to patients with RA and SpA, patients with PsA more frequently had a PDQ
score> 18 (28%) and less frequent a PDQ score< 13 (45%). This observation was further sub-
stantiated by higher proportions of a low STR in the high PDQ classification-groups for RA
and PsA. Furthermore significantly higher proportions of PsA patients had a low STR, whereas
lower proportions had a high STR in comparison to RA.
This also indicated that pain phenotype in PsA patients is harder to distinguish based only
on more conventional clinical indices and that other instruments such as the PDQ may be
needed.
Overall these findings suggest that contributions from central pain mechanisms may be
more prominent in patients with PsA. The existence of a preclinical phase in patients with PsA
prior to the diagnosis of the disease has recently been reported [36]. This phase is characterized
by nonspecific musculoskeletal symptoms, including joint pain, fatigue, and stiffness preced-
ing the development of PsA; a symptom constellation not unlike the one found in patients
with FM. In line, studies report more frequent concomitant FM based on self-report in this
patient group [10]. Still, it could be argued that the reporting of more frequent concomitant
FM in the PsA group has to do with the nature of the disease involving widespread enthesitis
mimicking FM and thus compromising the validity of tools designed to capture FM, including
clinical tender point examination. Contradicting this notion is the study by Marchesoni et al
reporting tender point to be the most valid clinical discriminator to distinguish PsA from FM
[37].
Characteristics of the different pain phenotypes
Among PDQ-completers significantly and clinically relevant higher levels of pain, fatigue, and
negative impact on global health were observed across PDQ classification-groups for all diag-
noses with the poorest levels of PROs in the high PDQ classification-group (>18). This ten-
dency was also observed for the TJC and composite disease activity scores (DAS28 and
ASDAS), which were found to be low in the low PDQ classification-group and moderate in
the intermediate and high PDQ classification-groups. However, no clinically relevant group
differences were observed in objective inflammatory indices (SJC, CRP) indicating a larger
contribution from non-inflammatory factors to the observed disease activity scores in the high
PDQ-group (>18) across all diagnoses.
Doctor’s perception of overall disease activity was strikingly lower than patients self-report
and the difference found across pain phenotypes was only borderline clinically relevant reflect-
ing that doctors primarily evaluate the overall disease activity based on more objective indices.
Association between pain status and PDQ
The logistic regression analysis for the presence of pain at or above the median VAS pain sup-
ported that a high PDQ score better explained the presence of high levels of pain than a low
score. Thus, patients presenting with neuropathic pain features had a 10-fold higher risk of
having high levels of pain.
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Clinical implications
In the absence of any diagnostic gold standards, mechanism-based pain classification is based
on the assumption that this can be done clinically, based on identifiable and discriminatory
patterns of symptoms and signs assumed to reflect the underlying pathophysiology. Current
scientific evidence, however, suggests that both neuropathic pain and pain conditions charac-
terised primarily by augmented central pain processing may share similar neurobiological
underpinnings [38]. Given that these neurobiological underpinnings give rise to clinical symp-
toms, it is not surprising if centrally mediated pain and neuropathic pain may share common
clinical features such as those captured by the PDQ. Substantiating this notion, striking pheno-
typic similarities has been demonstrated in patients with established peripheral neuropathy
and FM when evaluated with the PDQ [16]. It could, therefore, be speculated that rather than
indicating the presence of neuropathic pain, a high PDQ score in our patient population
reflected the presence of a primarily central pain component, including concomitant fibromy-
algia. It is well recognized that compared to individuals with localized or regional pain,
patients with centralized pain syndromes, including FM, report a higher illness burden; higher
pain intensity, more pronounced pain-related interference with everyday life, and higher levels
of psychological distress [39]. In the original study by Freynhagen et al., introducing the PDQ
to an unselected sample of 8000 patients with chronic low back pain, 37% were classified as
having a primarily neuropathic pain component [12]. Also in this sample, a high PDQ score
was found to be associated with more intense pain, more severe co-morbidity and poorer qual-
ity of life. From a critical point of view, it could be argued that a high score on the PDQ might
simply be related to the tendency to report more symptoms in general, which might also be
linked to psychosocial factors, or represent a non-specific finding in patients with more cen-
tralized pain syndromes.
Still, since pain is frequently used as a proxy for inflammation in the evaluation of rheu-
matic diseases, it is important to recognize that not all pain is inflammatory. Interestingly, the
study indicated a more intensive level of treatment across PDQ classification-groups. Although
there were no differences in the numbers of patients receiving biological treatment across
PDQ classification-groups, patients in the high PDQ classification-group were more likely to
have received more than one biological agent (PsA) and to have been changed back to
DMARDs after having been treated with biological agents (RA). These findings further indi-
cate that treatment failure is more prevailing in patients with signs of augmented central pain
processing [40]. Previous reports of worse treatment outcome for RA and PsA patients with
concomitant fibromyalgia support this observation [5;41].
It has been proposed that disease duration is related to the development of pain hypersensi-
tivity in RA [42]. The results of this study did not support this notion as no significant differ-
ences were found across the PDQ classification-groups. In contrast, a statistically significant
predominance of female gender was observed in the high PDQ group across all diagnoses,
indicating a higher frequency of central pain mechanisms among females. This finding is in
accordance with the observed gender distribution in other pain conditions characterized by
augmented central pain processing, for example, FM [43;44].
Limitations
The study had some limitations: the data sampled from the DANBIO registry were not com-
plete; however, considering the large sample size we find that the descriptive statistics were
representative. The more than 7,000 patients accepting to participate in the PDQ-survey had
higher ratings on VAS pain and other PRO’s than those declining, which might have skewed
the distribution of PDQ-scores. Detailed general demographic and clinical information,
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including information about possible comorbidities associated with neuropathic pain, were
not obtainable in this registry-based study and may also have influenced the study findings.
The study design being cross-sectional did not allow for advanced multivariable modelling,
which could have added more unique information on association between certain variables or
characteristics and pain phenotype. More prospective studies involving prognostic factor
research are desirable.
Furthermore, although the PDQ has been used to assess neuropathic pain features as a
proxy of central sensitization, the cut off values were established and validated in a sample of
neuropathic pain patients with a clearly defined peripheral factor, e.g. polyneuropathy and
post herpetic neuralgia. The traditional PDQ cut off values may therefore not be valid for the
concept of central sensitization in patients with inflammatory disorders. However, aside from
construct validity, our group has shown that the PDQ has acceptable psychometric properties,
including unidimensionality, scaling properties and test-retest reliability when applied in
patients with inflammatory arthritis (in review). Lastly, this registry-based study did not exam-
ine if patients also fulfilled the criteria for a diagnosis of FM; a pain condition that by many is
considered to represent the upper end of a pain hypersensitivity continuum. However, the
existence of a gradual transition from acute physiological pain to more chronic pain states
driven by changes in neural processing in the central nervous system is increasingly being rec-
ognized [2]. Nociceptive pain and pain caused by central pain mechanisms should therefore
not be regarded as exclusive categorical labels but rather as concurrent possible mechanistic
contributors to the patient’s pain. Because of the likely influence of pain hypersensitivity on
clinically relevant outcomes, the entire clinical pain hypersensitivity spectrum among patients
with inflammatory disorders should be captured. Instruments designed to assess underlying
pain mechanisms, and not only symptom based instruments designed to diagnose FM, there-
fore seem to be of relevance for this patient population.
Conclusion
In conclusion, more than 50% of this large Danish population of patients with inflammatory
arthritis reported significant pain and among those who completed the PDQ, approximately 20%
were classified as having primarily neuropathic pain features; a possible proxy for central sensiti-
zation. The PDQ-score was associated with composite disease activity scores and PROs, but not
with “objective markers” of peripheral inflammation (CRP and swollen joint count). Patients with
indication of a central pain mechanism were found to have a 10-fold higher risk of having a high
pain level than those with an indication of non-neuropathic pain. Pain classification by PDQ in
patients with inflammatory arthritis may assist the advancement of pain mechanism-based treat-
ment approaches and alignment of the expected outcome of anti-inflammatory treatment.
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